SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

Saborni Chakraborty; Vamsee Mallajosyula; Cristina M Tato; Gene S Tan; Taia T Wang

doi:10.1016/j.addr.2021.01.014

SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

Adv Drug Deliv Rev. 2021 May:172:314-338. doi: 10.1016/j.addr.2021.01.014. Epub 2021 Jan 20.

Authors

Saborni Chakraborty¹, Vamsee Mallajosyula², Cristina M Tato³, Gene S Tan⁴, Taia T Wang⁵

Affiliations

¹ Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.
² Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, CA, USA.
³ Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, CA, USA.
⁴ J. Craig Venter Institute, 4120 Capricorn Lane, La Jolla, CA 92037, USA; Department of Infectious Diseases, University of California San Diego, La Jolla, CA 92037, USA.
⁵ Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA. Electronic address: taiawang@stanford.edu.

Abstract

The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses.

Keywords: COVID-19; ORF3a; Phase III vaccine trials; Pre-fusion S protein; SARS-CoV-2 vaccine; Vaccine platform.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
COVID-19 / epidemiology
COVID-19 / immunology
COVID-19 / prevention & control*
COVID-19 Vaccines / administration & dosage*
COVID-19 Vaccines / chemistry
COVID-19 Vaccines / immunology
Clinical Trials, Phase III as Topic / methods*
Drug Evaluation, Preclinical / methods
Drug Evaluation, Preclinical / trends
Humans
Protein Structure, Secondary
Protein Structure, Tertiary
SARS-CoV-2 / chemistry
SARS-CoV-2 / drug effects*
SARS-CoV-2 / immunology

Substances

COVID-19 Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding